Abstract
Background:
Therapy-induced leukemia is a well-known clinical syndrome occurring as a late complication in patients treated with cytotoxic therapy.
Observation:
We herein present results of analysis of common gene polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and glutathione S-transferase (GST) genes in a 10-year-old boy who developed very rare type of cancer, mixed phenotype acute leukemia, 6 years after treatment of acute lymphoblastic leukemia.
Conclusions:
Impairment in function of GST and MTHFR enzymes found in our patient may have contributed to the development of secondary mixed phenotype acute leukemia, although precise mechanism remains elusive.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Biomarkers, Tumor / genetics*
-
Child
-
Flow Cytometry
-
Genotype
-
Glutathione S-Transferase pi / genetics
-
Glutathione Transferase / genetics*
-
Humans
-
Leukemia / drug therapy
-
Leukemia / genetics*
-
Male
-
Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
-
Neoplasms, Second Primary / drug therapy
-
Neoplasms, Second Primary / genetics*
-
Phenotype
-
Polymerase Chain Reaction
-
Polymorphism, Genetic / genetics*
-
Polymorphism, Restriction Fragment Length
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Prognosis
-
Remission Induction
Substances
-
Biomarkers, Tumor
-
MTHFR protein, human
-
Methylenetetrahydrofolate Reductase (NADPH2)
-
glutathione S-transferase T1
-
GSTA1 protein, human
-
GSTO1 protein, human
-
GSTP1 protein, human
-
Glutathione S-Transferase pi
-
Glutathione Transferase
-
glutathione S-transferase M1